The Prostate Specific Antigen Pipeline report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77). Prostate Specific Antigen Pipeline Market Research Report provides the latest projects and drug profiles with key companies.
Introduction:
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1074252 .
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.
Prostate Specific Antigen Companies Involved in Therapeutics Development
Advaxis Inc
Aeterna Zentaris Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
OncBioMune Pharmaceuticals Inc.
Prostate Specific Antigen Drug Profiles
ADXS-PSA - Drug Profile, AEZS-120 - Drug Profile, Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile, Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile, G-114 - Drug Profile, G-115 - Drug Profile, INO-5150 - Drug Profile, Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile, Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile, Prostatac - Drug Profile, rilimogene galvacirepvec - Drug Profile.

Request for Sample of this Research Report at http://www.reportsnreports.com/contacts/requestsample.aspx?name=1074252
The latest report Prostate Specific Antigen - Pipeline Review, H1 2017, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77).
The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects.
The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics.
Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1074252 .
Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77).
Identify the use of drugs for target identification and drug repurposing.
Identify potential new clients or partners in the target demographic.
Develop strategic initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with your contact details.